These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27878051)

  • 1. Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence.
    Wallis CJ; Lundeen C; Golda N; Brotherhood H; Pommerville P; Carr L
    Can Urol Assoc J; 2016 Aug; 10(7-8):277-280. PubMed ID: 27878051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yearly Trends of Overactive Bladder Medication Usage.
    Chua KJ; Patel HV; Tabakin A; Srivastava A; Doppalapudi SK; Hyams E; Tunuguntla HSGR
    Urol Pract; 2021 Sep; 8(5):546-554. PubMed ID: 37145398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
    Welk B; McArthur E
    BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
    Ju R; Garrett J; Wu JM
    Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia.
    Welk B; McClure JA
    Eur Urol Open Sci; 2022 Dec; 46():22-29. PubMed ID: 36506252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study.
    Tadrous M; Elterman D; Khuu W; Mamdani MM; Juurlink DN; Gomes T
    Can Urol Assoc J; 2018 Mar; 12(3):E142-E145. PubMed ID: 29319477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are anticholinergic medications used for overactive bladder associated with new onset depression? A population-based matched cohort study.
    Welk B; McArthur E
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1710-1714. PubMed ID: 33015899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer agents for the management of overactive bladder.
    Epstein BJ; Gums JG; Molina E
    Am Fam Physician; 2006 Dec; 74(12):2061-8. PubMed ID: 17186712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
    Mauseth SA; Skurtveit S; Spigset O
    Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
    Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T
    Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.
    Cetinel B; Onal B
    Korean J Urol; 2013 Dec; 54(12):806-15. PubMed ID: 24363860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Anticholinergic Drugs Used for the Therapy of Overactive Bladder on P-Glycoprotein Activity.
    Wakuda H; Okura T; Maruyama-Fumoto K; Kagota S; Ito Y; Miyauchi-Wakuda S; Otani N; Uemura N; Yamada S; Shinozuka K
    Biol Pharm Bull; 2019; 42(12):1996-2001. PubMed ID: 31787715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
    Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
    Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
    Minhas R; Tadrous M; Elterman D; Gomes T
    Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.